Research review underscores progress in treating kidney cancer, importance of close patient monitoring

November 28, 2018 by Annie Deck-Miller, Roswell Park Cancer Institute
This image shows a cross section of a kidney. Credit: Holly Fischer/Wikipedia

With the swift introduction of approved immunotherapy approaches into the treatment landscape for many cancers, medical professionals across many care-delivery settings and specialties are tasked with the need to follow and understand a set of treatment standards that are changing rapidly. The treatment of renal cell carcinoma (RCC), or kidney cancer, has been one of the fields most dramatically affected by what the authors of a new research review article call a period of "remarkable progress," with FDA approval of the first immunotherapy combination regimen for the treatment of patients newly diagnosed with kidney cancer coming just a few months ago, in April 2018.

In an effort to compile and summarize the latest knowledge about these immunotherapy combinations and their implications, a group of immunotherapy experts led by Saby George, MD, of Roswell Park Comprehensive Cancer Center have written a new research review article assessing current approaches to treating patients newly diagnosed with kidney cancer and also looking ahead to some of the most pressing questions still to be answered related to these emerging therapies. Published online Nov. 21 by the journal JAMA Oncology, the review article highlights the path to approval for the new standard of care for these patients—ipilimumab, also known as Yervoy, together with nivolumab, also known as Opdivo.

"Remarkable progress has been made recently in the clinical application of newer immunotherapies, of which the most notable are (ICIs) that increase antitumor immunity by blocking native immune regulators such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1)," the authors write. "However, current evidence indicates that not all patients may find single-agent immunotherapy advantageous, underscoring the unmet need for combination treatment strategies that can improve efficacy in a broader patient population without exacerbating ."

"Our goal in crafting this review was not only to summarize the path to approval for these breakthrough immunotherapies, but also to present that information in context with other emerging immuno-oncology therapy combinations that are still being studied," notes Dr. George, first author on the new publication. "Critically, given what we are learning about the effects of checkpoint inhibitors given in combination, we also highlight the importance of identifying and appropriately managing immune-related toxicities."

Treating physicians who prescribe checkpoint inhibitors for with advanced kidney —whether alone or in combination with other therapies — "must adopt a multidisciplinary management approach, enlisting the assistance of specialists such as endocrinologists, pulmonologists, nephrologists, gastroenterologists, dermatologists, and neurologists," the authors conclude.

Explore further: Major response to immunotherapy in early-stage mismatch repair deficient colon cancer

More information: Saby George et al. Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma, JAMA Oncology (2018). DOI: 10.1001/jamaoncol.2018.4604

Related Stories

Major response to immunotherapy in early-stage mismatch repair deficient colon cancer

October 22, 2018
Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses in 100 percent of early-stage colon cancers with mismatch repair deficiencies, ...

FDA approves new standard of care for kidney cancer

April 17, 2018
The standard of care for kidney cancer patients continues to improve. The U.S. Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic ...

Stage four sarcomatoid kidney cancer patient first to show complete response to immunotherapy

October 2, 2018
"You see this place on the image? That's where your kidney was," says VCU Massey Cancer Center medical oncologist Asit Paul, M.D., Ph.D., to 69-year-old Thomas Bland. "And the tumors we saw in your lung and other places still ...

New cancer immunotherapy drugs rapidly reach patients after approval

May 10, 2018
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study. The finding suggests that cancer immunotherapies ...

Quickly spotting rare side effects from immunotherapy

January 3, 2018
Immunotherapy, which uses the body's own immune system to fight disease, is transforming the treatment of several types of cancers. Severe adverse effects can result from these groundbreaking cancer treatments, however, and ...

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer

July 26, 2017
A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses ...

Recommended for you

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.